Australia: High Court concludes that methods of medical treatment are patentable

Life Sciences Alert
Last Updated: 14 December 2013
Article by Simone Mitchell, Nicholas Tyacke and Jaimie Wolbers

On 4 December 2013, the High Court judgment in Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd & Ors [2013] HCA 50 was delivered. This is the first occasion the High Court has considered whether methods of medical treatment of the human body are patentable inventions within the meaning of section 18(1) of the Patents Act 1990 (Cth). The majority of the High Court concluded they were, whilst providing important guidance on contributory (or indirect) infringement in the context of patents which claim methods of medical treatment.


Parties and the patent

By way of background, the patent in issue was Australian Patent No 670491, entitled Pharmaceutical for the treatment of skin disorders. Relevantly, the patent claims:

[a] method of preventing or treating a skin disorder wherein the skin disorder is psoriasis, which comprises administering to a recipient an effective amount of [leflunomide].

Sanofi-Aventis Australia Pty Ltd (Sanofi) markets leflunomide in Australia under the brand name ARAVA®.

In 2008, Apotex Pty Ltd (Apotex) obtained registrations for a generic leflunomide product. Shortly thereafter, Sanofi commenced infringement proceedings largely relying on section 117 of the Patents Act 1990 (Cth) which relates to contributory (or indirect) infringement.

Apotex responded by filing a cross-claim for revocation. Importantly, one of the grounds relied upon in making the argument for revocation was that the patent did not disclose a patentable invention, effectively challenging the patentability of methods of medical treatments.

Pursuant to the Patents Act, amongst other things, a patentable invention must be a manner of manufacture within the meaning of section 6 of the Statute of Monopolies. Apotex argued that methods of medical treatment do not fall within this definition as they are "essentially non-economic" and "not capable of being industrially applied." They further argued that a method of medical treatment involving the administration of a pharmaceutical substance differs to a medicine in that it "improved the condition of a human being, which is not an article of commerce."1

This is the first occasion that the High Court has been required to considered whether a method of medical treatment "is a proper subject of letters patent according the principles which have been developed for the application of s 6 of the Statue of Monopolies."2



The majority of the High Court (French CJ, Crennan, Kiefel and Gageler JJ, Hayne J dissenting) concluded that "methods of medical treatment of human beings, including surgery and the administration of therapeutic drugs, can be the subject of patents."3 This is consistent with the approach that has been taken by the Full Federal Court in a number of recent cases.4

Their reasoning included detailed consideration of the body of case law in both Australia and the United Kingdom that relates to manner of manufacture. Consideration was also give to the positions held in the European Union, the United States, Canada and New Zealand.

Manner of manufacture is a broad and evolving concept. As identified in the Explanatory Memorandum to the Patents Bill 1990:

[i]t means little more than that an invention must belong to the useful arts rather than the fine arts.

The judgments from the majority placed emphasis on the following paragraph derived from the judgment of Lockhart J in Anaesthetic Supplies Pty Ltd v Rescare Ltd which neatly encompassed the principles from the leading National Research Development Corp v Commissioner of Patents5 case:

"If a process which does not produce a new substance but nevertheless results in 'a new and useful effect' so that the new result is 'an artificially created state of affairs' providing economic utility, it may be considered a 'manner of new manufacture' within s 6 of the Statute of Monopolies."6

The Chief Justice concisely drew the views of the majority together when his Honour stated:

"The exclusion from patentability of methods of medical treatment represents an anomaly for which no clear and consistent foundation has been enunciated. Whatever views may have held in the past, methods of medical treatment, particularly the use of pharmaceutical drugs, cannot today be conceived as 'essentially noneconomic'." 7


The Patent Office has been granting patents for methods of medical treatment, particularly in relation to pharmaceutical products, for many years. This decision now provides the Australian Life Sciences sector with certainty that patents are available for inventions that are methods of medical treatment provided that the invention is otherwise patentable (that is, it meets the requirements of novelty, utility, inventive step and no prior use).



Sanofi's case in infringement was dependent on section 117 of the Patents Act.

At first instance and on appeal, Apotex was found to infringe the patent. However, the High Court overturned these decisions and found that Apotex had not infringed the patent.

Pursuant to section 117 of the Patents Act, a person may, in certain circumstances, be liable for contributory (or indirect) infringement if that person supplies a product to another, where the use of that product would infringe a third party's patent rights.

Section 117(1) of the Patents Act provides that where "the use of a product by a person would infringe a patent, the supply of that product by one person to another is an infringement."

Further, section 117(2) describes what constitutes use of a product. Relevantly, Sanofi relied on:

  • s 117(2)(b), which provides "if the product is not a staple commercial product - any use of the product, if the supplier had reason to believe that the person would put it to that use"; and
  • s 117(2)(c), which provides "in any case - the use of the product in accordance with any instructions for the use of the product, or any inducement to use."

The High Court found that because the product information for Apo-Leflunomide strictly stated that:

Apo-Leflunomide is indicated for the treatment of:
  • Active Rheumatoid Arthritis.
  • Active Psoriatic Arthritis. Apo-Leflunomide is not ndicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease.

It could not be said that there was an instruction within the product information to use the Apo- Leflunomide in a way that would infringe the patent. Therefore the indirect infringement claim pursuant to s 117(2)(c) of the Patents Act failed.

In relation to s 117(2)(b) of the Patents Act, the majority concluded that Sanofi had not shown (nor could it be inferred) that Apotex had reason to believe that its product would be used contrary to the indications in the Apo-Leflunomide product information. As such, the claim for indirect infringement under this section also failed.


It is clear that going forward, innovator companies seeking to make a claim of indirect infringement in respect of a method of medical treatment in circumstances where the product information or instructions for use do not provide directions to infringe the patent, will need to ensure that they have sufficient evidence to establish that the product would be used contrary to the directions and in a manner which would infringe the patent.


While this decision provides certainty that methods of medical treatment are patentable subject matter, the High Court highlighted that there are broad public policy considerations to be made in relation patents in this field. The Chief Justice noted that consideration of "competing philosophies of proprietarianism and instrumentalism and the relative values to be accorded to different public goods: alleged incentives to innovation on the one hand, and the widest possible availability of new methods of medical treatment to relieve suffering on the other"8 are best left to the legislature.


1Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50, [217].
2National Research Development Corp v Commissioner of Patents (1959) 102 CLR 252 at 269.
3Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50, [1] (French CJ).
4Anaesthetic Supplies Pty Ltd v Rescare Ltd (1994) 50 FCR 1 and Bristol-Myers Squibb v FH Faulding & Co Ltd (2000) 97 FCR 524.
5(1959) 102 CLR 252.
6Anaesthetic Supplies Pty Ltd v Rescare Ltd (1994) 50 FCR 1 at 19.
7Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50, [50].
8Apotex Pty Ltd v Sanofi-Aventis Australia [2013] HCA 50, [50].

© DLA Piper

This publication is intended as a general overview and discussion of the subjects dealt with. It is not intended to be, and should not used as, a substitute for taking legal advice in any specific situation. DLA Piper Australia will accept no responsibility for any actions taken or not taken on the basis of this publication.

DLA Piper Australia is part of DLA Piper, a global law firm, operating through various separate and distinct legal entities. For further information, please refer to

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.